Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Spry N, Harvey J, Macleod C, Borg M, Ngan SY, Millar JL, Graham P, Zissiadis Y, Kneebone A, Carroll S, Davies T, Reece WH, Iacopetta B, Goldstein D. Spry N, et al. Among authors: goldstein d. Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1438-46. doi: 10.1016/j.ijrobp.2007.08.070. Epub 2007 Dec 31. Int J Radiat Oncol Biol Phys. 2008. PMID: 18164859 Clinical Trial.
Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
Short M, Goldstein D, Halkett G, Reece W, Borg M, Zissiadis Y, Kneebone A, Spry N. Short M, et al. Among authors: goldstein d. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):157-62. doi: 10.1016/j.ijrobp.2012.03.003. Epub 2012 Apr 28. Int J Radiat Oncol Biol Phys. 2013. PMID: 22543205 Clinical Trial.
The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group. Goldstein D, et al. Br J Cancer. 2012 Jan 3;106(1):61-9. doi: 10.1038/bjc.2011.526. Epub 2011 Dec 1. Br J Cancer. 2012. PMID: 22134511 Free PMC article. Clinical Trial.
Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma.
Giraud P, Racadot S, Vernerey D, Goldstein D, Glimelius B, Van Houtte P, Gubanski M, Spry N, Van Laethem JL, Hammel P, Huguet F. Giraud P, et al. Among authors: goldstein d. Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):993-1002. doi: 10.1016/j.ijrobp.2021.01.055. Epub 2021 Feb 6. Int J Radiat Oncol Biol Phys. 2021. PMID: 33561507
Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.
Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, McKendrick J, Leong T, Hartopeanu C, Zalcberg J, Mackay J. Ngan SY, et al. Among authors: goldstein d. J Clin Oncol. 2012 Nov 1;30(31):3827-33. doi: 10.1200/JCO.2012.42.9597. Epub 2012 Sep 24. J Clin Oncol. 2012. PMID: 23008301 Clinical Trial.
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group.
Wirth A, Grigg A, Wolf M, Goldstein D, Johnson C, Davis S, Dutu G, Kypreos P, Smith C, Kneebone A, Herzberg M, Joseph D, Catalano J, Roos D, Stone J, Reynolds J. Wirth A, et al. Among authors: goldstein d. Leuk Lymphoma. 2011 May;52(5):786-95. doi: 10.3109/10428194.2010.547155. Epub 2011 Feb 14. Leuk Lymphoma. 2011. PMID: 21314490 Clinical Trial.
Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT).
Oar A, Lee M, Le H, Hruby G, Dalfsen R, Pryor D, Lee D, Chu J, Holloway L, Briggs A, Barbour A, Chander S, Ng SP, Samra J, Shakeshaft J, Goldstein D, Nguyen N, Goodman KA, Chang DT, Kneebone A. Oar A, et al. Among authors: goldstein d. Pract Radiat Oncol. 2020 May-Jun;10(3):e136-e146. doi: 10.1016/j.prro.2019.07.018. Epub 2019 Nov 21. Pract Radiat Oncol. 2020. PMID: 31761541
AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A, Lee M, Le H, Wilson K, Aiken C, Chantrill L, Simes J, Nguyen N, Barbour A, Samra J, Sjoquist KM, Moore A, Espinoza D, Gebski V, Yip S, Chu J, Kneebone A, Goldstein D. Oar A, et al. Among authors: goldstein d. BMC Cancer. 2021 Aug 19;21(1):936. doi: 10.1186/s12885-021-08666-y. BMC Cancer. 2021. PMID: 34412605 Free PMC article.
4,143 results